Gaviscon formulations also revealed the downregulation of various genes such as COL6A2 [112], DOHH [113], MEX3D [114], SBNO2 [115], which have roles in cancer or chronic disease progression (Table 2, Supporting Table S4). This evidence concerns the gene COL6A2 and cancer.